Author: NSV

Novadip releases five-year follow-up results for NVD003, regenerative treatment for severe bone non-union of lower limb
Novadip Biosciences, a late-stage clinical biotechnology company specializing in regenerative medicine, has announced the five-year follow-up results from the Phase 1/2 clinical trial of its investigational tissue regeneration product, NVD003, in adult patients with severe bone non-union (BNU) of the lower limb, following trauma. The five-year safety and efficacy data
Read More
Novadip appoints Soumya Chandramouli as Chief Financial Officer
Novadip Biosciences, a late-stage clinical biotechnology company specializing in regenerative medicine, has announced the appointment of Soumya Chandramouli as Chief Financial Officer (CFO). Soumya Chandramouli has 25 years’ experience in financial management, most recently as Chief Financial Officer of IBA Group, a listed company in the medical device and healthcare
Read More
San José City Council unanimously approves next phase of San José Airport Connector Project
San José Connection Partners, a consortium including Plenary Americas, Webcor/Obayashi, and HNTB, and Glydways has announced that the San José City Council voted unanimously to move the Diridon–Airport Connector into Phase 2a of project development. The decision marks a significant step toward achieving the City’s sustainable mobility goals, reflecting strong
Read More
NorthSea Therapeutics announces publication of positive results from Phase 2b ICONA clinical trial of icosabutate in biopsy-confirmed F1-F3 MASH in Journal of Hepatology
NorthSea Therapeutics B.V. (‘NST’, or the ‘Company’), a private, late-stage clinical biotechnology company developing novel strategies to treat metabolic, cholestatic, and fibrotic diseases, has announced that results from the Phase 2b ICONA clinical trial of icosabutate in biopsy-confirmed F1-F3 metabolic dysfunction-associated steatohepatitis (MASH) were published in the Journal of Hepatology.
Read More
Ventyx Biosciences announces presentation of data from the Phase 2 trial of allosteric TYK2 inhibitor VTX958 in Crohn’s Disease at ECCO 2025
Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, has announced that data from the Phase 2 trial of its TYK2 inhibitor VTX958 in Crohn’s disease will be presented during the 20th Congress of
Read More
Ventyx Biosciences highlights 2025 pipeline strategy and provides clinical updates on its NLRP3 inhibitor portfolio
Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, has highlighted its 2025 pipeline strategy and provided clinical updates on its NLRP3 inhibitor portfolio, including VTX2735 and VTX3232. “We believe that 2025 will be
Read More
Phase Four Series C first closing
Phase Four, a leader in advanced in-space propulsion design and manufacturing, has announced the first close of its Series C funding round, securing nearly 60% of the target raise with strong participation from new and existing investors. The round is led by Artemis Group Capital, the Oklahoma-based investment firm helmed
Read More
VORAGO Technologies and Collabora partner to advance open source in space
VORAGO Technologies, a leading provider of radiation hardened and radiation tolerant MCUs and MPUs for Aerospace and Defense, and Collabora, a leader in open source software and support, today announced they are partnering to advance the use of open source to achieve resilience for mission critical applications in space. “As
Read More
Sagence AI emerges from stealth tackling economic viability of inference hardware for generative AI
Sagence AI™ has emerged from stealth unveiling a groundbreaking advanced analog in-memory compute architecture that directly addresses the untenable power/performance/price and environmental sustainability conundrum facing AI inferencing. Driven by its industry-first architectural innovations using analog technology, Sagence AI makes possible multiple orders of magnitude improvement in energy efficiency and cost
Read More
Ventyx Biosciences announces late-breaking abstract highlighting high rates of clinical and endoscopic remission among LTE completers at Week 52
Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced that a late-breaking abstract including new long-term extension (LTE) data from the Phase 2 trial of tamuzimod in ulcerative
Read More
Achronix releases groundbreaking Speedster AC7t800 Mid-Range FPGA, driving innovation in AI/ML, 5G/6G and Data Center Applications
Achronix Semiconductor Corporation, a leader in FPGA-based hardware accelerator devices and high-performance eFPGA IP, has announced the availability and shipment of AC7t800 FPGA, designed to address the rapidly growing needs of data-centric applications such as generative AI, DPUs and SmartNICs. With samples available today and units already shipped to customers,
Read More
Ventyx Biosciences announces $27 million strategic investment from Sanofi
Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced that Sanofi has agreed to make a $27 million strategic investment in the Company at an as-converted price of
Read More